BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Aventis  Pharma  Deutschland  GmbH  submitted  on  29  March  1999  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Lantus,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The company submitted on 6 September 1999 a second application for a MA for Optisulin, which is 
identical in every respect to Lantus.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Hans van Bronswijk 
Co-Rapporteur:  Dr. Per Nilsson 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2.  
Steps taken for the assesment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 23 April 1999 
The Rapporteur's first assessment report was circulated to all CPMP Members on 23 July 1999. 
The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  27  July 
1999.  
The draft-consolidated list of questions was circulated for comments on 17 September 1999.  
During  the  meeting  on  21-23  September  1999  the  CPMP  agreed  on  the  consolidated  list  of 
questions to be sent to the company. The same list of questions was adopted for Optisulin. The 
final consolidated list of questions was sent to the company on 24 September 1999.  
The company submitted the responses to the consolidated list of questions on 28 October 1999. 
The Rapporteur and Co-Rapporteur circulated the response assessment report on the company’s 
responses to the list of questions to all CPMP Members on 22 December 1999. 
During  the  meeting  on  15-17  February  2000,  the  company  gave  an  oral  explanation  of 
outstanding issues relating to toxico-pharmacological and clinical aspects. 
During  the  meeting  on  15-17  February  2000  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Lantus on 17 February 2000. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
